Multi-epitope fusion protein, antibody, encoding gene and recombinant plasmid of white spot syndrome virus and uses thereof
Through the multi-epitope fusion protein and antibodies of the leukoplakia virus and combined with magnetic microparticle chemiluminescence method, the existing detection methods are solved, and efficient and simple antigen detection of leukoplakia virus is achieved.
Patent Information
- Application Number
- CN202411011454.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-07-26
AI Technical Summary
Existing methods for detecting viruses in white spot syndrome such as PCR and ELISA have problems such as complex operation, low sensitivity and long reaction time, which limits their application in grassroots aquaculture and production sites.
Provide a multi-epitope fusion protein, antibodies, coding genes and recombinant plasmid of the white patch syndrome virus. The antibodies prepared using these substances can specifically bind to the white patch syndrome virus antigen, improve detection sensitivity and simplify operations, and adopt magnetic microparticle chemistry based on Detection method of luminescence method.
It significantly improves the detection sensitivity and detection limit of white spot syndrome virus antigen, and simplifies the operation process of the detection method, making the detection more convenient and efficient.
Smart Images

Figure CN118530375B_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field related to white spot syndrome virus antigen detection, and specifically to a multi-epitope fusion protein, antibody, encoding gene and recombinant plasmid of white spot syndrome virus and their uses. Background Art
[0002] White spot syndrome virus (WSSV) belongs to the genus Whispovirus of the family Nimaviridae. It is a highly virulent pathogen. The virus particles range from rod-shaped to oval-shaped, with three layers of capsules, a long envelope extending at one end, and the envelope is about 6 to 7nm thick, containing double-stranded DNA. The virus can cause white spot disease (WSD) in crustaceans, especially decapod aquatic animals. The mortality rate of infected animals can reach 100%, and it has become one of the most harmful diseases to shrimp farming worldwide.
[0003] At present, conventional methods for detecting WSSV mainly include polymerase chain reaction (PCR) and enzyme linked immunosorbent assay (ELISA). Among them, the PCR method requires expensive and precise PCR instruments, is relatively complex to operate, and relies on professionals, which greatly limits its application in grassroots breeding and production and processing sites. The ELISA method has low detection sensitivity, long reaction time, and complex manual operation. Summary of the invention
[0004] In view of this, the present application provides a multi-epitope fusion protein, antibody, encoding gene and recombinant plasmid of white spot syndrome virus and their uses. The present application uses the multi-epitope fusion protein of the present application as an antibody of the immunogen, which can specifically bind to the white spot syndrome virus antigen, not only improving the detection sensitivity and detection limit of binding to the white spot syndrome virus antigen, but also making the detection method simple and easy to operate.
[0005] In the first aspect of the present application, the present application provides a multi-epitope fusion protein of white spot syndrome virus, wherein the multi-epitope fusion protein has a structure shown in formula (I):
[0006] ;
[0007] Wherein, m is selected from 0 or 1;
[0008] AAS1 and AAS2 each independently represent the amino acid sequence shown in SEQ ID NO.13 or the amino acid sequence shown in SEQ ID NO.14, and AAS1 and AAS2 represent different amino acid sequences;
[0009] AAS3 represents the amino acid sequence shown in SEQ ID NO.15;
[0010] L1 and L2 each independently represent a flexible linking peptide.
[0011] In the second aspect of the present application, the present application provides an antibody, which includes a coating antibody and a detection antibody, the immunogen of the coating antibody and the immunogen of the detection antibody are each independently selected from the multi-epitope fusion protein described in the first aspect of the present application, and the immunogen of the coating antibody and the immunogen of the detection antibody are the same or different.
[0012] In the third aspect of the present application, the present application provides a coding gene of the multi-epitope fusion protein as described in the first aspect of the present application, wherein the coding gene has a structure shown in formula (II):
[0013] ;
[0014] Wherein, m' is selected from 0 or 1;
[0015] NAS1 and NAS2 each independently represent the nucleotide sequence shown in SEQ ID NO.3 or the nucleotide sequence shown in SEQ ID NO.4, and NAS1 and NAS2 represent different nucleotide sequences;
[0016] NAS3 represents the nucleotide sequence shown in SEQ ID NO.6;
[0017] The nucleotide sequence shown in SEQ ID NO.3 expresses the amino acid sequence shown in SEQ ID NO.13;
[0018] The nucleotide sequence shown in SEQ ID NO.4 expresses the amino acid sequence shown in SEQ ID NO.14;
[0019] The nucleotide sequence shown in SEQ ID NO.6 expresses the amino acid sequence shown in SEQ ID NO.15;
[0020] L1' represents the gene fragment expressing the flexible connecting peptide L1, and L2' represents the gene fragment expressing the flexible connecting peptide L2;
[0021] E1 and E2 are each independently selected from restriction enzyme cleavage sites.
[0022] In the fourth aspect of the present application, the present application provides a recombinant plasmid, wherein the recombinant plasmid comprises the coding gene as described in the third aspect of the present application.
[0023] In the fifth aspect of the present application, the present application provides a use of any of the following items in the preparation of a product for detecting white spot syndrome virus antigens:
[0024] (I) the multi-epitope fusion protein described in the first aspect of the present application; and / or,
[0025] (II), the antibody described in the second aspect of the present application; and / or,
[0026] (III), the coding gene described in the third aspect of the present application; and / or,
[0027] (IV) The recombinant plasmid described in the fourth aspect of the present application.
[0028] In the sixth aspect of the present application, the present application provides a detection reagent for detecting white spot syndrome virus antigen based on magnetic microparticle chemiluminescence method, and the detection reagent comprises the antibody described in the second aspect of the present application.
[0029] In the seventh aspect of the present application, the present application provides a detection kit for detecting white spot syndrome virus antigen based on magnetic microparticle chemiluminescence method, and the detection kit comprises the antibody described in the second aspect of the present application.
[0030] This application has the following beneficial effects:
[0031] First, the antibody using the multi-epitope fusion protein of the present application as the immunogen can specifically bind to the white spot syndrome virus antigen, which not only improves the detection sensitivity and detection limit of the binding white spot syndrome virus antigen, but also makes the detection method easy to operate.
[0032] Second, compared with the case where both the coating antibody and the detection antibody are polyclonal antibody II, at least one of the coating antibody and the detection antibody is polyclonal antibody I, which can significantly improve the detection sensitivity of white spot syndrome virus antigen.
[0033] Third, compared with the three combinations of coating antibody being polyclonal antibody I and detection antibody being polyclonal antibody II, coating antibody being polyclonal antibody II and detection antibody being polyclonal antibody I, and coating antibody being polyclonal antibody II and detection antibody being polyclonal antibody II, the coating antibody being polyclonal antibody I and detection antibody being polyclonal antibody I can significantly improve the detection sensitivity of white spot syndrome virus antigen. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 This is the result of DNA agarose gel electrophoresis in Example 2 of the present application.
[0035] Figure 2 This is the result of SDS-PAGE protein gel electrophoresis in Example 3 of the present application. DETAILED DESCRIPTION
[0036] The present application discloses a multi-epitope fusion protein, antibody, encoding gene and recombinant plasmid of white spot syndrome virus and their uses. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters for implementation. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all deemed to be included in this application. The methods and applications of this application have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of this application to implement and apply the technology of this application.
[0037] Multi-epitope fusion protein:
[0038] In the first aspect of the present application, the present application provides a multi-epitope fusion protein of white spot syndrome virus, wherein the multi-epitope fusion protein has a structure shown in formula (I):
[0039] ;
[0040] Wherein, m is selected from 0 or 1;
[0041] AAS1 and AAS2 each independently represent the amino acid sequence shown in SEQ ID NO.13 or the amino acid sequence shown in SEQ ID NO.14, and AAS1 and AAS2 represent different amino acid sequences;
[0042] AAS3 represents the amino acid sequence shown in SEQ ID NO.15;
[0043] L1 and L2 each independently represent a flexible linker peptide.
[0044] In some specific embodiments of the present application, m is selected from 0.
[0045] In some specific embodiments of the present application, m is selected from 1.
[0046] In some optional embodiments of the present application, L1 and L2 each independently represent an amino acid sequence from the N-terminus to the C-terminus. , n is selected from an integer from 1 to 4.
[0047] In some specific embodiments of the present application, n is selected from 2.
[0048] In some specific embodiments of the present application, L1 represents the amino acid sequence shown in SEQ ID NO.17.
[0049] In some specific embodiments of the present application, L2 represents the amino acid sequence shown in SEQ ID NO.17.
[0050] In some specific embodiments of the present application, the AAS1 represents the amino acid sequence shown in SEQ ID NO.13, and AAS2 represents the amino acid sequence shown in SEQ ID NO.14.
[0051] In some optional embodiments of the present application, the multi-epitope fusion protein is selected from the amino acid sequence shown in any of SEQ ID NOs. 17 to 18.
[0052] In some specific embodiments of the present application, the multi-epitope fusion protein is selected from the amino acid sequence shown in SEQ ID NO.17.
[0053] Antibody:
[0054] In the second aspect of the present application, the present application provides an antibody, which includes a coating antibody and a detection antibody, the immunogen of the coating antibody and the immunogen of the detection antibody are each independently selected from the multi-epitope fusion protein described in the first aspect of the present application, and the immunogen of the coating antibody and the immunogen of the detection antibody are the same or different.
[0055] In some optional embodiments of the present application, at least one of the immunogen of the coating antibody and the immunogen of the detection antibody is selected from A multi-epitope fusion protein of the structure shown, wherein AAS1, AAS2, AAS3, L1 and L2 are as defined in the first aspect of the present application. Further, the immunogen of the coating antibody and the immunogen of the detection antibody are selected from Multi-epitope fusion proteins with the structures shown.
[0056] In some optional embodiments of the present application, the immunogen of the coating antibody and the immunogen of the detection antibody are each independently selected from a multi-epitope fusion protein having an amino acid sequence as shown in any one of SEQ ID NO.17 to 18, and at least one of the immunogen of the coating antibody and the immunogen of the detection antibody is selected from a multi-epitope fusion protein having an amino acid sequence as shown in SEQ ID NO.17. For example, the immunogen of the coating antibody has a multi-epitope fusion protein with an amino acid sequence as shown in SEQ ID NO.17, and the immunogen of the detection antibody has a multi-epitope fusion protein with an amino acid sequence as shown in SEQ ID NO.17; or the immunogen of the coating antibody has a multi-epitope fusion protein with an amino acid sequence as shown in SEQ ID NO.17, and the immunogen of the detection antibody has a multi-epitope fusion protein with an amino acid sequence as shown in SEQ ID NO.18; or the immunogen of the coating antibody has a multi-epitope fusion protein with an amino acid sequence as shown in SEQ ID NO.18, and the immunogen of the detection antibody has a multi-epitope fusion protein with an amino acid sequence as shown in SEQ ID NO.17.
[0057] In some specific embodiments of the present application, the immunogen of the coating antibody is selected from a multi-epitope fusion protein having an amino acid sequence as shown in SEQ ID NO.17, and the immunogen of the detection antibody is selected from a multi-epitope fusion protein having an amino acid sequence as shown in SEQ ID NO.17.
[0058] In some optional embodiments of the present application, the coating antibody is selected from polyclonal antibodies; and / or, the detection antibody is selected from polyclonal antibodies.
[0059] In some specific embodiments of the present application, the coating antibody is selected from a polyclonal antibody, and the detection antibody is selected from a polyclonal antibody.
[0060] In some optional embodiments of the present application, the animals used for immunization with the coating antibody and the animals used for immunization with the detection antibody include, but are not limited to, mammals and birds. For example, rabbits (e.g., New Zealand white rabbits), sheep, guinea pigs, and mice. Further, the animals used for immunization with the coating antibody and the animals used for immunization with the detection antibody are both selected from rabbits (e.g., New Zealand white rabbits).
[0061] Coding genes:
[0062] In the third aspect of the present application, the present application provides a coding gene for the multi-epitope fusion protein described in the first aspect of the present application, wherein the coding gene has a structure shown in formula (II):
[0063] ;
[0064] Wherein, m' is selected from 0 or 1;
[0065] NAS1 and NAS2 each independently represent the nucleotide sequence shown in SEQ ID NO.3 or the nucleotide sequence shown in SEQ ID NO.4, and NAS1 and NAS2 represent different nucleotide sequences;
[0066] NAS3 represents the nucleotide sequence shown in SEQ ID NO.6;
[0067] The nucleotide sequence shown in SEQ ID NO.3 expresses the amino acid sequence shown in SEQ ID NO.13;
[0068] The nucleotide sequence shown in SEQ ID NO.4 expresses the amino acid sequence shown in SEQ ID NO.14;
[0069] The nucleotide sequence shown in SEQ ID NO.6 expresses the amino acid sequence shown in SEQ ID NO.15;
[0070] L1' represents the gene fragment expressing the flexible connecting peptide L1, and L2' represents the gene fragment expressing the flexible connecting peptide L2;
[0071] E1 and E2 are each independently selected from restriction enzyme cleavage sites.
[0072] In some specific embodiments of the present application, m' is selected from 0.
[0073] In some specific embodiments of the present application, m' is selected from 1.
[0074] In some optional embodiments of the present application, L1' and L2' are each independently selected from a nucleotide sequence from the 5' end to the 3' end, and n' is selected from an integer from 1 to 4 (eg, 1, 2, 3 or 4).
[0075] In some specific embodiments of the present application, n' is selected from 2.
[0076] In some specific embodiments of the present application, L1' is selected from the nucleotide sequence shown in SEQ ID NO.7.
[0077] In some specific embodiments of the present application, L2' is selected from the nucleotide sequence shown in SEQ ID NO.7.
[0078] In some specific embodiments of the present application, NAS1 represents the nucleotide sequence shown in SEQ ID NO.3, and NAS2 represents the nucleotide sequence shown in SEQ ID NO.4.
[0079] In some optional embodiments of the present application, E1 and E2 are each independently selected from an EcoRI cleavage site, a Not Ⅰ cleavage site or an Xho cleavage site.
[0080] In some optional embodiments of the present application, E1 and E2 are each independently selected from an EcoRI restriction site or a Not I restriction site, wherein the EcoRI restriction site has a nucleotide sequence as shown in SEQ ID NO.8, and the Not I restriction site has a nucleotide sequence as shown in SEQ ID NO.9.
[0081] In some specific embodiments of the present application, E1 is selected from the EcoRⅠ restriction site, and E2 is selected from the Not Ⅰ restriction site.
[0082] In some optional embodiments of the present application, the encoding gene is selected from the nucleotide sequence shown in any of SEQ ID NOs. 10 to 11.
[0083] In some specific embodiments of the present application, the encoding gene is selected from the nucleotide sequence shown in SEQ ID NO.10.
[0084] Recombinant plasmid:
[0085] In the fourth aspect of the present application, the present application provides a recombinant plasmid, wherein the recombinant plasmid comprises the coding gene as described in the second aspect of the present application.
[0086] use:
[0087] In the fifth aspect of the present application, the present application provides a use of any of the following items in the preparation of a product for detecting white spot syndrome virus antigens:
[0088] (I) the multi-epitope fusion protein described in the first aspect of the present application; and / or,
[0089] (II), the antibody described in the second aspect of the present application; and / or,
[0090] (III), the coding gene described in the third aspect of the present application; and / or,
[0091] (IV) The recombinant plasmid described in the fourth aspect of the present application.
[0092] Detection reagents for detecting white spot syndrome virus antigen based on magnetic microparticle chemiluminescence method:
[0093] In the sixth aspect of the present application, the present application provides a detection reagent for detecting white spot syndrome virus antigen based on magnetic microparticle chemiluminescence method, and the detection reagent comprises the antibody described in the second aspect of the present application.
[0094] Detection kit for white spot syndrome virus antigen based on magnetic microparticle chemiluminescence method:
[0095] In the seventh aspect of the present application, the present application provides a detection kit for detecting white spot syndrome virus antigen based on magnetic microparticle chemiluminescence method, and the detection kit comprises the antibody described in the second aspect of the present application.
[0096] In order to make the purpose, technical solutions and advantages of the present application clearer, the implementation scheme of the present application will be further described in detail below in conjunction with examples.
[0097] Example 1 Preparation of encoding gene:
[0098] In this embodiment, the preparation method of the coding gene comprises the following steps:
[0099] Step S101, screening and codon optimization of antigenic epitope sequences in the white spot syndrome virus gene VP28:
[0100] The whole genome sequence of the white spot syndrome virus Chinese strain (accession number: AF332093.3) retrieved from the DNA sequence database Genbank was analyzed, and the amino acid of WVS421 (VP28) was selected and the B cell antigen epitope prediction analysis was performed using the biological online software Immunomedicine Group and the software SVMTriP. Combining the prediction information of the two softwares, two dominant linear antigen epitopes with relatively concentrated antigen epitopes were selected. Among them, the two dominant linear antigen epitopes correspond to the nucleotide sequences shown in SEQ ID NO.1~2 respectively.
[0101] Among them, the nucleotide sequence shown in SEQ ID NO.1 was optimized according to the codons preferred by Pichia pastoris to obtain the nucleotide sequence shown in SEQ ID NO.3; the nucleotide sequence shown in SEQ ID NO.2 was optimized according to the codons preferred by Pichia pastoris to obtain the nucleotide sequence shown in SEQ ID NO.4.
[0102] Step S102, codon optimization of white spot syndrome virus gene VP19:
[0103] The whole genome sequence of the white spot syndrome virus Chinese strain (accession number: AF332093.3) retrieved from the DNA sequence database Genbank was analyzed, and the full-length amino acid sequence of WVS414 (VP19) was selected, and the full-length amino acid sequence corresponds to the nucleotide sequence shown in SEQ ID NO.5.
[0104] The nucleotide sequence shown in SEQ ID NO.5 was optimized according to the codons preferred by Pichia pastoris to obtain the nucleotide sequence shown in SEQ ID NO.6.
[0105] Step S103, synthesis of coding gene:
[0106] Recombination is performed based on the nucleotide sequence shown in SEQ ID NO.3 and the nucleotide sequence shown in SEQ ID NO.4 in step S101, and based on the nucleotide sequence shown in SEQ ID NO.6 in step S102. The recombination sequence is as follows:
[0107] (1) SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.6, respectively;
[0108] (2) SEQ ID NO. 3, SEQ ID NO. 6, respectively;
[0109] (3) are SEQ ID NO.4 and SEQ ID NO.6 respectively.
[0110] During the gene recombination process, the nucleotide sequence SEQ ID NO.7 encoding the flexible connecting peptide is inserted between two adjacent nucleotide sequences, and the EcoRⅠ restriction site and the Not Ⅰ restriction site are respectively inserted at both ends of the recombined nucleotide sequence. The EcoRⅠ restriction site has the nucleotide sequence shown in SEQ ID NO.8; the Not Ⅰ restriction site has the nucleotide sequence shown in SEQ ID NO.9.
[0111] Thus, by recombination according to the recombination sequence (1), a coding gene having the nucleotide sequence shown in SEQ ID NO.10 is obtained; by recombination according to the recombination sequence (2), a coding gene having the nucleotide sequence shown in SEQ ID NO.11 is obtained; and by recombination according to the recombination sequence (3), a coding gene having the nucleotide sequence shown in SEQ ID NO.12 is obtained.
[0112] Unless otherwise specified, the coding genes of the present application were commissioned to be synthesized by General Biotechnology (Anhui) Co., Ltd., and three positive strains (AMP+) containing plasmids of the white spot syndrome virus fusion protein gene sequence were obtained.
[0113] Sequence number Nucleotide sequence information (in the 5'-to-3' direction) SEQ ID NO.1 ATGGATCTTTCTTTCACTCTTTCGGTCGTGTCGGCCATCCTCGCCATCACTGCTGTGATTGCTGTATTTATTGTGATTTTTAGGTATCACAAC SEQ ID NO.2 GATGCGGATCTTGTCATCACTCCCGTGGAGGGCCGAGCACTCGAAGTGACTGTGGGGCAGAATCTCACCTTTGAG SEQ ID NO.3 ATGGATTTGTCTTTCACTTTGTCGGTCGTGTCGGCCATTTTGGCCATTACTGCTGTGATTGCTGTATTTATTGTGATTTTTAGGTATCACAAC SEQ ID NO.4 GATGCGGATTTGGTCATTACTCCCGTGGAAGGCCGAGCACTCGAAGTGACTGTGGGGCAGAATTTGACCTTTGAA SEQ ID NO.5 ATGGCCACCACGACTAACACTCTTCCTTTCGGCAGGACCGGAGCCCAGGCCGCTGGCCCTTCTTACACCATGGAAGATCTTGAAGGCTCCATGTCTATGGCTCGCATGGGTCTCTTTTTGATCGTTGCTATCTCAATTGGTATCCTCGTCCTGGCCGTCATGAATGTATGGATGGGACCAAAGAAGGACAGCGATTCTGACACTGATAAGGACACCGATGATGATGACGACACTGCCAACGATAACGATGATGAGGACAAATATAAGAACAGGACCAGGGATATGATGCTTCTGGCTGGGTCCGCTCTTCTGTTCCTCGTTTCCGCCGCCACCGTTTTTATGTCTTACCCCAAGAGGAGGCAGTAA SEQ ID NO.6 ATGGCCACCACGACTAACACTCTTCCTTTCGGCAGGACCGGAGCCCAGGCCGCTGGCCCTTCTTACACCATGGAAGATCTTGAAGGCTCCATGTCTATGGCTCGCATGGGTCTCTTTTTGATCGTTGCTATCTCAATTGGTATCCTCGTCCTGGCCGTCATGAATGTATGGATGGGACCAAAGAAGGATAGCGATTCTGATACTGATAAGGATACCGATGATGATGATGATACTGCCAACGATAACGATGATGAAGATAAATATAAGAACAGGACCAGGGATATGATGCTTCTGGCTGGGTCCGCTCTTCTGTTCCTCGTTTCCGCCGCCACCGTTTTTATGTCTTACCCCAAGAGGAGGCAGTAA SEQ ID NO.7 GGTGGTGGTGGTTCTGGTGGTGGTGGTTCT SEQ ID NO.8 GAATTC SEQ ID NO.9 GCGGCCGC SEQ ID NO.10 <![CDATA[ GAATTC ATGGATTTGTCTTTCACTTTGTCGGTCGTGTCGGCCATTTTGGCCATTACTGCTGTGATTGCTGTATTTATTGTGATTTTTAGGTATCACAAC GGT GGTGGTGGTTCTGGTGGTGGTGGTTCT GATGCGGATTTGGTCATTACTCCCGTGGAAGGCCGAGCACTCGAAGTGACTGTGGGGCAGAATTTGACCTTTGAA GGTGGTGGTGGTTCTGGTGGTGGTGGTTCT ATGGCCACCACGACTAACACTCTTCCTTTCGGCAGGACCGGAGCCCAGGCCGCTGGCCCTTCTTACACCATGGAAGATCTTGAAGGCTCCATGTCTATGGCTCGCATGGGTCTCTTTTTGATCGTTGCTATCTCAATTGGTATCCTCGTCCTGGCCGTCATGAATGTATGGATGGGACCAAAGAAGGATAGCGATTCTGATACTGATAAGGATACCGATGATGATGATGATACTGCCAACGATAACGATGATGAAGATAAATATAAGAACAGGACCAGGGATATGATGCTTCTGGCTGGGTCCGCTCTTCTGTTCCTCGTTTCCGCCGCCACCGTTTTTATGTCTTACCCCAAGAGGAGGCAGTAA GCGGCCGC ]]> SEQ ID NO.11 <![CDATA[ GAATTC ATGGATTTGTCTTTCACTTTGTCGGTCGTGTCGGCCATTTTGGCCATTACTGCTGTGATTGCTGTATTTATTGTGATTTTTAGGTATCACAAC GGT GGTGGTGGTTCTGGTGGTGGTGGTTCT ATGGCCACCACGACTAACACTCTTCCTTTCGGCAGGACCGGAGCCCAGGCCGCTGGCCCTTCTTACACCATGGAAGATCTTGAAGGCTCCATGTCTATGGCTCGCATGGGTCTCTTTTTGATCGTTGCTATCTCAATTGGTATCCTCGTCCTGGCCGTCATGAATGTATGGATGGGACCAAAGAAGGATAGCGATTCTGATACTGATAAGGATACCGATGATGATGATGATACTGCCAACGATAACGATGATGAAGATAAATATAAGAACAGGACCAGGGATATGATGCTTCTGGCTGGGTCCGCTCTTCTGTTCCTCGTTTCCGCCGCCACCGTTTTTATGTCTTACCCCAAGAGGAGGCAGTAA GCGGCCGC <!-- 8 -->]]> SEQ ID NO.12 <![CDATA[ GAATTC GATGCGGATTTGGTCATTACTCCCGTGGAAGGCCGAGCACTCGAAGTGACTGTGGGGCAGAATTTGACCTTTGAA GGTGGTGGTGGTTCTGGTGGT GGTGGTTCT ATGGCCACCACGACTAACACTCTTCCTTTCGGCAGGACCGGAGCCCAGGCCGCTGGCCCTTCTTACACCATGGAAGATCTTGAAGGCTCCATGTCTATGGCTCGCATGGGTCTCTTTTTGATCGTTGCTATCTCAATTGGTATCCTCGTCCTGGCCGTCATGAATGTATGGATGGGACCAAAGAAGGATAGCGATTCTGATACTGATAAGGATACCGATGATGATGATGATACTGCCAACGATAACGATGATGAAGATAAATATAAGAACAGGACCAGGGATATGATGCTTCTGGCTGGGTCCGCTCTTCTGTTCCTCGTTTCCGCCGCCACCGTTTTTATGTCTTACCCCAAGAGGAGGCAGTAA GCGGCCGC ]]>
[0114] Among them, the nucleotide sequence SEQ ID NO.3 is expected to express the amino acid sequence SEQ ID NO.13;
[0115] The nucleotide sequence SEQ ID NO.4 is expected to express the amino acid sequence SEQ ID NO.14;
[0116] The nucleotide sequence SEQ ID NO.6 is expected to express the amino acid sequence SEQ ID NO.15;
[0117] The nucleotide sequence SEQ ID NO.7 is expected to express the amino acid sequence SEQ ID NO.16;
[0118] The coding gene SEQ ID NO.10 is expected to express a multi-epitope fusion protein having an amino acid sequence as shown in SEQ ID NO.17;
[0119] The coding gene SEQ ID NO.11 is expected to express a multi-epitope fusion protein having an amino acid sequence as shown in SEQ ID NO.18;
[0120] The coding gene SEQ ID NO.12 is expected to express a multi-epitope fusion protein having an amino acid sequence as shown in SEQ ID NO.19.
[0121] Sequence number Amino acid sequence information (in the direction from the N-terminus to the C-terminus) SEQIDNO.13 MDLSFTLSVVSAILAITAVIAVFIVIFRYHN SEQIDNO.14 DADLVITPVEGRALEVTVGQNLTFE SEQIDNO.15 MATTTNTLPFGRTGAQAAGPSYTMEDLEGSMSMARMGLFLIVAISIGILVLAVMNVWMGPKKDSDSDTDKDTDDDDDTANDNDDEDKYKNRTRDMMLLAGSALLFLVSAATVFMSYPKRRQ SEQIDNO.16 GGGGSGGGGS SEQIDNO.17 <![CDATA[MDLSFTLSVVSAILAITAVIAVFIVIFRYHN GGGGSGGGGS DADLVITPVEGRALEVTVGQNLTFE GGGGSGGGGS MATTTNTLPFGRTGAQAAGPSYTMEDLEGSMSMARMGLFLIVAISIGILVLAVMNVWMGPKKDSDSDTDKDTDDDDDTANDNDDEDKYKNRTRDMMLLAGSALLFLVSAATVFMSYPKRQ]]> SEQIDNO.18 <![CDATA[MDLSFTLSVVSAILAITAVIAVFIVIFRYHN GGGGSGGGGS MATTTNTLPFGRTGAQAAGPSYTMEDLEGSMSMARMGLFLIVAISIGILVLAVMNVWMGPKKDSDSDTDKDTDDDDDTANDNDDEDKYKNRTRDMMLLAGSALLFLVSAATVFMSYPKRQ]]> SEQIDNO.19 <![CDATA[DADLVITPVEGRALEVTVGQNLTFE GGGGSGGGGS MATTTNTLPFGRTGAQAAGPSYTMEDLEGSMSMARMGLFLIVAISIGILVLAVMNVWMGPKKDSDSDTDKDTDDDDDTANDNDDEDKYKNRTRDMMLLAGSALLFLVSAATVFMSYPKRQ]]>
[0122] Example 2 Construction of recombinant plasmid:
[0123] In this embodiment, the construction of the recombinant plasmid includes the following steps:
[0124] Step S201, culture the three positive bacterial species (AMP+) containing the white spot syndrome virus fusion protein gene sequence plasmid obtained in Example 1 and the Escherichia coli species (Zeocin+) containing pPICZαA respectively according to the culture method of Escherichia coli, and extract the white spot syndrome virus fusion protein gene positive plasmid and pPICZαA plasmid using the TAKARA plasmid extraction kit (purchased from Bao Ri Yi Biotechnology (Beijing) Co., Ltd.).
[0125] Step S202, polymerase chain reaction (PCR reaction) was performed using the white spot syndrome virus fusion protein gene positive plasmid as a template, the reaction procedure: 95°C 5 min; 95°C 30s, 55°C 1min, 72°C 1min, 30 cycles; 72°C 10min.
[0126] Step S203, agarose electrophoresis (120V 30min) according to the Tiangen agarose gel DNA recovery kit to recover the white spot syndrome virus fusion protein nucleic acid.
[0127] Step S204: According to the instructions of the endonuclease (purchased from Quanshijin Biotechnology Co., Ltd.), the white spot syndrome virus fusion protein DNA and the pPICZαA plasmid were double-digested. The product was subjected to agarose electrophoresis (120v 30min) and the white spot syndrome virus fusion protein nucleic acid and the pPICZαA plasmid were recovered according to the Tiangen agarose gel DNA recovery kit.
[0128] Step S205, according to the instruction of T4 DNA ligase (purchased from Quanshijin Biotechnology Co., Ltd.), the white spot syndrome virus fusion protein nucleic acid and pPICZαA after enzyme digestion were ligated.
[0129] Step S206, the ligated product is transferred into DH5α competent cells (Full Gold) for culture, and the cultured DH5α is coated on LB agar plates (Zeocin+) and cultured overnight.
[0130] Step S207, selecting a monoclonal bacterial strain, and performing PCR reaction and DNA agarose gel electrophoresis on the monoclonal bacterial strain according to the universal primer AOX1 of the vector pPICZαA.
[0131] Table 3 Sequence information of universal primer AOX1:
[0132]
[0133] Among them, the results of DNA agarose gel electrophoresis are as follows Figure 1 In the figure, Marker represents the lane of the size marker, the control represents the lane of the vector pPICZαA, pPICZαA-WSSV-1 represents the lane encoding the gene SEQ ID NO.10, pPICZαA-WSSV-2 represents the lane encoding the gene SEQ ID NO.11, and pPICZαA-WSSV-3 represents the lane encoding the gene SEQ ID NO.12.
[0134] from Figure 1 It can be seen that the insertion direction of the coding genes SEQ ID NO.10 to 12 in the recombinant plasmid is correct; the coding gene SEQ ID NO.10 has an obvious size band of 859bp, the coding gene SEQ ID NO.11 has an obvious size band of 753bp, and the coding gene SEQ ID NO.12 has an obvious size band of 665bp, which confirms that the product fragment size is in line with expectations.
[0135] Example 3 Expression of multi-epitope fusion protein:
[0136] In this embodiment, the expression of the multi-epitope fusion protein specifically includes the following steps:
[0137] Step S301, preparation of yeast competent state: select a single colony with good growth status and obvious characteristics obtained in step S206 of Example 2, inoculate it into YPD medium (5 mL), and culture it overnight at 30°C; take bacterial liquid (0.1-0.5 mL) and culture it overnight in fresh YPD medium (500 mL), bacterial density OD600 = 1.3-1.5; centrifuge at 1500g for 5 min at 4°C, and resuspend the bacteria with ice-cold sterile water (500 mL); centrifuge at 1500g for 5 min at 4°C, and resuspend the bacteria with ice-cold sterile water (250 mL); centrifuge at 1500g for 5 min at 4°C, and resuspend the bacteria with ice-cold sorbitol aqueous solution (1M, 20 mL); centrifuge at 1500g for 5 min at 4°C, and resuspend the bacteria with ice-cold sorbitol (1 mL). Dispense into 1 mL tubes, 100uL per tube, and store at -80°C.
[0138] Step S302, linearization of the recombinant plasmid: enzyme digestion at 37°C for 2h, inactivation at 65°C for 20min; wherein the enzyme used for enzyme digestion is endonuclease (purchased from Quanshijin Biotechnology Co., Ltd.).
[0139] Step S303, electroporation transformation of yeast: add the linearized recombinant plasmid (15uL) to the prepared yeast competent cells (100uL), mix well, precool on ice for 5min, transfer to a 0.2cm electroporation cup (precooled on ice), place on ice for 10min, put into an electroporator, take out after electroporation, quickly put back on ice and add into precooled 1M sorbitol aqueous solution (1mL), mix well, place on a shaker at 30℃ for 40min, aspirate 300uL and spread on an MD plate, and culture at 30℃ for 2 days.
[0140] S304, Mut+ phenotype induced expression: select a single colony, place it in a 250mL shake flask containing BMGY medium (25mL), and culture it at 30℃, 250rpm until OD600 = 2-6; centrifuge at 1500-3000g for 5min at room temperature, collect the bacteria, and resuspend the bacteria in BMMY medium to make OD600 about 1.0; place the obtained bacterial solution in a 1L shake flask, seal it with double-layer gauze, and continue to culture on a shaker at 30℃, 250rpm; add methanol to the culture medium every 24 hours to a final concentration of 0.5%; after 72 hours, centrifuge the bacterial solution at 12000rpm for 3min and collect the supernatant.
[0141] S305. Use SDS-PAGE protein gel electrophoresis to identify the multi-epitope fusion proteins expressed by the coding genes SEQ ID NOs. 10 to 12 of the present application.
[0142] Among them, the SDS-PAGE protein gel electrophoresis results are as follows Figure 2In the figure, Marker represents the size marker lane, lane 1 represents the lane of the multi-epitope fusion protein SEQ ID NO.17 expressed by the coding gene SEQ ID NO.10, lane 2 represents the lane of the multi-epitope fusion protein SEQ ID NO.19 expressed by the coding gene SEQ ID NO.12, lane 3 represents the lane of the multi-epitope fusion protein SEQ ID NO.18 expressed by the coding gene SEQ ID NO.11, and lane 4 represents the lane of the vector pPICZαA.
[0143] from Figure 2 It can be seen that lane 1 has an obvious protein band of about 22KD, lane 2 has no obvious protein band, and lane 3 has an obvious protein band of about 17KD. It can be confirmed that the product fragment sizes of the multi-epitope fusion protein SEQ ID NO.17 expressed by the coding gene SEQ ID NO.10 and the multi-epitope fusion protein SEQ ID NO.18 expressed by the coding gene SEQ ID NO.11 are in line with expectations.
[0144] S306. Place the multi-epitope fusion protein in a 10KD ultrafiltration tube and centrifuge at 1200 rpm for 20 minutes to obtain a purified multi-epitope fusion protein.
[0145] Example 4 Preparation of Antibodies:
[0146] In this embodiment, the antibody is a polyclonal antibody. The polyclonal antibody uses the multi-epitope fusion protein obtained in Example 3 as an immunogen, and New Zealand rabbits are used as immunized animals. Four immunizations (including primary immunization and three booster immunizations) are performed. In each immunization, each New Zealand rabbit is immunized with 500 μL of the multi-epitope fusion protein.
[0147] The method for preparing polyclonal antibodies specifically comprises the following steps:
[0148] Step S401, primary immunization: after emulsifying the multi-epitope fusion protein (500 μL) and an equal volume of Freund's complete adjuvant, the mixture was subcutaneously injected at multiple points on the back of New Zealand rabbits, with 100 μL of the mixed emulsion of the multi-epitope fusion protein injected at each point.
[0149] Step S402, secondary immunization: 7 days after the initial immunization, the multi-epitope fusion protein (500 μL) was mixed and emulsified with an equal volume of Freund's incomplete adjuvant, and then injected subcutaneously at multiple points on the back of New Zealand rabbits, with 100 μL of the mixed emulsion of the multi-epitope fusion protein injected at each point.
[0150] Step S403, three immunizations: 7 days after the second immunization, the multi-epitope fusion protein (500 μL) was mixed with an equal volume of Freund's incomplete adjuvant for emulsification, and then injected subcutaneously at multiple points on the back of New Zealand rabbits, with 100 μL of the mixed emulsion of the multi-epitope fusion protein injected at each point.
[0151] Step S404, four immunizations: 7 days after the three immunizations, four immunizations were performed, the fusion protein (500 μL) was mixed with an equal volume of Freund's incomplete adjuvant for emulsification, and then injected subcutaneously at multiple points on the back of New Zealand rabbits, with 100 μL of the mixed emulsion of the multi-epitope fusion protein injected at each point.
[0152] Step S405: Collect whole blood from New Zealand rabbits, place the collected whole blood at 37°C for 2 hours, place it at 4°C overnight, centrifuge it at 4000 rpm for 10 minutes the next day, and collect the supernatant to obtain New Zealand rabbit serum. Using the New Zealand rabbit serum before immunization as a control and the multi-epitope fusion protein as an antigen, the serum antibody titer was detected by indirect ELISA method, and the serum antibody titer was 1:10000.
[0153] Step S406: Purification of polyclonal antibodies:
[0154] Step S406-1, add immunomagnetic beads (0.5 mL) to the centrifuge tube, place the centrifuge tube close to the magnetic rack so that the magnetic beads are adsorbed on the tube wall, and use a pipette to discard the liquid in the centrifuge tube;
[0155] Step S406-2, add PBS buffer solution (2 mL) to the centrifuge tube and vortex mix, place the centrifuge tube close to the magnetic rack, allow the magnetic beads to adsorb on the tube wall, and use a pipette to discard the liquid in the centrifuge tube. Repeat this step three times.
[0156] Step S406-3, add New Zealand rabbit serum (1 mL) to the centrifuge tube and mix well, and incubate at room temperature for 2 hours under shaking; then, place the centrifuge tube on a magnetic rack, use a pipette to aspirate the liquid in the centrifuge tube and retain it, and collect the immunomagnetic beads.
[0157] Step S406-4: Add PBS buffer solution (2 mL) to the collected immunomagnetic beads and vortex to mix, place the centrifuge tube close to the magnetic rack to allow the magnetic beads to adsorb on the tube wall, and use a pipette to discard the liquid in the centrifuge tube. Repeat this step three times.
[0158] Step S406-5, add elution buffer (2 mL) and mix well, let stand for 1-2 min, place the centrifuge tube on a magnetic rack to allow the immunomagnetic beads to adsorb on the tube wall, and use a pipette to transfer the liquid in the centrifuge tube to an EP tube filled with neutralization buffer (50 μL). Repeat this step four to six times, and combine and concentrate the collected liquids.
[0159] The elution buffer has a formula of 50 mM NaH2PO4, 300 mM NaCl, and 20 mM imidazole. The pH is adjusted to 8.0 with NaOH and sterilized by 0.22 µm or 0.45 µm filtration.
[0160] Neutralization buffer formulation: 50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH adjusted to 8.0 with NaOH, sterilized by 0.22 µm or 0.45 µm filtration.
[0161] Thus, polyclonal antibody I with multi-epitope fusion protein SEQ ID NO.17 as immunogen and polyclonal antibody II with multi-epitope fusion protein SEQ ID NO.18 as immunogen were obtained.
[0162] Example 5 Detection reagent / detection kit for detecting white spot syndrome virus antigen based on magnetic microparticle chemiluminescence method:
[0163] In this embodiment, the working principle of the white spot syndrome virus antigen detection kit based on magnetic particle chemiluminescence method is: using the double antibody sandwich method immune principle combined with magnetic particle separation technology, the sample to be tested is mixed and incubated with biotin-labeled polyclonal antibodies, acridinium ester-labeled polyclonal antibodies and streptavidin magnetic beads to form an immune complex, and after the unbound impurities are removed by washing with solid phase carrier magnetic particles, a luminescent substrate is added to promote luminescence, and the relative luminescence intensity (RLU) is measured. Within a certain range, the RLU value is proportional to the white spot syndrome virus antigen content, and the white spot syndrome virus antigen content is obtained based on the RLU value.
[0164] In this embodiment, the main components of the kit for detecting white spot syndrome virus antigen based on magnetic particle chemiluminescence method are: magnetic bead working solution, antibody working solution, acridinium ester marker working solution, pre-excitation solution, excitation solution, calibrator, positive quality control product, and negative quality control product.
[0165] Magnetic bead working solution: prepared from streptavidin affinity magnetic beads (225uL) and PBS-BSA solution (pH=7.4, 4275μL).
[0166] Antibody working solution: prepared from biotin-labeled polyclonal antibody (5.0 μg) and PBS-BSA solution (pH=7.4, 10995 μL).
[0167] Acridinium ester label working solution: prepared from acridinium ester labeled polyclonal antibody (1.0 μg) and PBS-BSA solution (pH=7.4, 10999 μL).
[0168] Pre-stimulation solution: Add hydrogen peroxide (10 mL) and concentrated hydrochloric acid (8.25 mL) to 500 mL of purified water, mix well, and then add purified water to make up to 1000 mL.
[0169] Excitation solution: Add sodium hydroxide (4.0 g) and TritonX (10 mL) to purified water and make up to 1000 mL.
[0170] The working process of the kit for detecting white spot syndrome virus antigen based on magnetic particle chemiluminescence method specifically includes the following steps:
[0171] Mix the sample to be tested (50 μL), antibody working solution (50 μL), magnetic bead working solution (20 μL) and acridinium ester marker working solution (50 μL) evenly, and react at 37°C for 5 to 30 minutes; wash with 0.1 mol / L PBS buffer solution; add pre-excitation solution (100 μL) and excitation solution (100 μL), mix evenly, and react at 37°C for 5 minutes; detect and obtain the RLU value.
[0172] White spot syndrome virus-positive serum was selected as the standard, and PBST buffer (0.05 volume% Tween-20, pH=7.4) was used as the diluent to perform a 2-fold gradient dilution of the positive serum to obtain 2-fold, 4-fold, 8-fold, 16-fold, 32-fold, 64-fold, 128-fold, 256-fold, 512-fold, 1024-fold, 2048-fold, 4096-fold, 8192-fold, and 16384-fold diluted positive serum samples, respectively.
[0173] Establishment of standard curve: Select 512-fold, 1024-fold, 2048-fold, 4096-fold, 8192-fold, and 16384-fold diluted positive serum samples as calibrators, and name them calibrators 1, 2, 3, 4, 5, and 6. When testing, add them in order, and the instrument automatically recognizes the test and generates a standard curve.
[0174] Preparation of sensitivity quality control products: Select 2-fold, 4-fold, 8-fold, 16-fold, 32-fold, 64-fold, 128-fold, 256-fold, 512-fold, 1024-fold, 2048-fold, 4096-fold, 8192-fold, and 16384-fold diluted positive serum samples as sensitivity quality control products.
[0175] Based on the above sensitivity quality control product, the sensitivity of the magnetic microparticle chemiluminescence method for detecting white spot syndrome virus antigen in the present application was verified. The measurement results are shown in Table 4.
[0176] Table 4: Results of testing for white spot syndrome virus antigens:
[0177]
[0178] It can be seen from Table 4 that the detection limit of the white spot syndrome virus antigen detected by the magnetic particle chemiluminescence method of the present application can reach 8192 times.
[0179] Compared with the case where both the coating antibody and the detection antibody are polyclonal antibody II, at least one of the coating antibody and the detection antibody is polyclonal antibody I, which can significantly improve the detection sensitivity of white spot syndrome virus antigen.
[0180] Compared with the three combinations of coating antibody being polyclonal antibody I and detection antibody being polyclonal antibody II, coating antibody being polyclonal antibody II and detection antibody being polyclonal antibody I, and coating antibody being polyclonal antibody II and detection antibody being polyclonal antibody II, the coating antibody being polyclonal antibody I and detection antibody being polyclonal antibody I can significantly improve the detection sensitivity of white spot syndrome virus antigen.
[0181] The above is a detailed introduction to the multi-epitope fusion protein, antibody, encoding gene and recombinant plasmid of a white spot syndrome virus provided by the present application and their uses. This article uses specific examples to illustrate the principles and implementation methods of the present application. The description of the above embodiments is only used to help understand the method and core idea of the present application. It should be pointed out that for those skilled in the art, without departing from the principles of the present application, several improvements and modifications can be made to the present application, and these improvements and modifications also fall within the scope of protection of the claims of the present application.
Claims
1. A multi-epitope fusion protein of white spot syndrome virus, It is characterized in that The multi-epitope fusion protein is selected from the structure shown in formula (I): ; Wherein, m is selected from 0 or 1; AAS 1 represents the amino acid sequence shown in SEQ ID NO.13; AAS 2 represents the amino acid sequence shown in SEQ ID NO.14; AAS 3 represents the amino acid sequence shown in SEQ ID NO.15; L 1 and L 2 Each independently represents a flexible connecting peptide; L 1 and L 2 Each independently represents the amino acid sequence from N-terminus to C-terminus , n is selected from an integer from 1 to 4.
2. The multi-epitope fusion protein according to claim 1, It is characterized in that The multi-epitope fusion protein is selected from the amino acid sequence shown in any one of SEQ ID NOs. 17 to 18.
3. An antibody combination, It is characterized in that The antibody combination consists of a coating antibody and a detection antibody; the coating antibody is selected from a polyclonal antibody, and the detection antibody is selected from a polyclonal antibody; The immunogen of the coating antibody and the immunogen of the detection antibody are each independently selected from the multi-epitope fusion protein according to any one of claims 1 to 2, and the immunogen of the coating antibody and the immunogen of the detection antibody are the same or different.
4. The antibody combination according to claim 3, It is characterized in that At least one of the immunogen of the coating antibody and the immunogen of the detection antibody is selected from a multi-epitope fusion protein with an amino acid sequence as shown in SEQ ID NO.
17.
5. The antibody combination according to claim 4, It is characterized in that The immunogen of the coating antibody and the immunogen of the detection antibody are both selected from the multi-epitope fusion protein with an amino acid sequence as shown in SEQ ID NO.
17.
6. A gene encoding the multi-epitope fusion protein according to any one of claims 1 to 2, It is characterized in that The coding gene is selected from the structure shown in formula (II): ; Wherein, m' is selected from 0 or 1; NAS 1 represents the nucleotide sequence shown in SEQ ID NO.3; NAS 2 represents the nucleotide sequence shown in SEQ ID NO.4; NAS 3 represents the nucleotide sequence shown in SEQ ID NO.6; The nucleotide sequence shown in SEQ ID NO.3 expresses the amino acid sequence shown in SEQ ID NO.13; The nucleotide sequence shown in SEQ ID NO.4 expresses the amino acid sequence shown in SEQ ID NO.14; The nucleotide sequence shown in SEQ ID NO.6 expresses the amino acid sequence shown in SEQ ID NO.15; L 1 ' represents the expression of flexible linker peptide L 1 The gene fragment, L 2 ' represents the expression of flexible linker peptide L 2 Gene fragment of L 1 ' and L 2 'Each independently selected from the nucleotide sequence from the 5' end to the 3' end , n' is selected from an integer from 1 to 4; E 1 and E 2 Each is independently selected from the restriction enzyme cleavage site.
7. The coding gene according to claim 6, It is characterized in that The coding gene is selected from the nucleotide sequence shown in any one of SEQ ID NOs. 10 to 11.
8. A recombinant plasmid, It is characterized in that The recombinant plasmid comprises the coding gene according to any one of claims 6 to 7.
9. Use of the antibody combination according to any one of claims 3 to 5 in the preparation of a product for detecting white spot syndrome virus antigens.
10. A detection reagent for detecting white spot syndrome virus antigen based on magnetic microparticle chemiluminescence method, It is characterized in that The detection reagent comprises the antibody combination according to any one of claims 3 to 5.
11. A detection kit for detecting white spot syndrome virus antigen based on magnetic microparticle chemiluminescence method, It is characterized in that The detection kit comprises the antibody combination according to any one of claims 3 to 5.
